These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29890892)

  • 21. Design and analysis of group sequential logrank tests in maximum duration versus information trials.
    Kim K; Boucher H; Tsiatis AA
    Biometrics; 1995 Sep; 51(3):988-1000. PubMed ID: 7548714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation of hurst exponent for sequential monitoring of clinical trials with covariate adaptive randomization.
    Yang Y; Zhu H; Lai D
    Contemp Clin Trials; 2022 Sep; 120():106887. PubMed ID: 35988662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A parametric multiple test procedure to adaptive group-sequential trials allowing for mid-term modifications.
    Jin M
    Contemp Clin Trials; 2020 Mar; 90():105955. PubMed ID: 32028024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A flexible semiparametric transformation model for recurrent event data.
    Dong L; Sun L
    Lifetime Data Anal; 2015 Jan; 21(1):20-41. PubMed ID: 24241908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted design for adaptive clinical trials via semiparametric model.
    Zhang H; Yuan A; Tan MT
    Int J Biostat; 2020 Oct; 17(2):177-190. PubMed ID: 33027048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential Monte Carlo for response adaptive randomized trials.
    Golchi S; Thorlund K
    Biostatistics; 2020 Apr; 21(2):287-301. PubMed ID: 30202898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semiparametric analysis of zero-inflated recurrent events with a terminal event.
    Ma C; Hu T; Lin Z
    Stat Med; 2021 Aug; 40(18):4053-4067. PubMed ID: 33963791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome.
    Diao G; Zeng D; Hu K; Ibrahim JG
    Stat Med; 2017 Sep; 36(22):3475-3494. PubMed ID: 28560768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Semiparametric analysis of recurrent events data in the presence of dependent censoring.
    Ghosh D; Lin DY
    Biometrics; 2003 Dec; 59(4):877-85. PubMed ID: 14969466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Joint modeling of recurrent events and survival: a Bayesian non-parametric approach.
    Paulon G; De Iorio M; Guglielmi A; Ieva F
    Biostatistics; 2020 Jan; 21(1):1-14. PubMed ID: 29985982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semiparametric transformation models with random effects for joint analysis of recurrent and terminal events.
    Zeng D; Lin DY
    Biometrics; 2009 Sep; 65(3):746-52. PubMed ID: 18945267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size calculation for the Andersen-Gill model comparing rates of recurrent events.
    Tang Y; Fitzpatrick R
    Stat Med; 2019 Oct; 38(24):4819-4827. PubMed ID: 31397911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic semiparametric transformation models for recurrent event data with a terminal event.
    Jin J; Song X; Sun L
    Stat Med; 2022 Nov; 41(27):5432-5447. PubMed ID: 36121319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subgroup analysis with semiparametric models toward precision medicine.
    Yuan A; Chen X; Zhou Y; Tan MT
    Stat Med; 2018 May; 37(11):1830-1845. PubMed ID: 29575056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events.
    Tayob N; Murray S
    Biostatistics; 2015 Jan; 16(1):73-83. PubMed ID: 24719282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exact critical values for group sequential designs with small sample sizes.
    Rom DM; McTague JA
    J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
    Wu J; Xiong X
    J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Semiparametric estimation of time-varying intervention effects using recurrent event data.
    Xu J; Lam KF; Chen F; Milligan P; Cheung YB
    Stat Med; 2017 Jul; 36(17):2682-2696. PubMed ID: 28464565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonparametric sequential monitoring of longitudinal trials.
    Bogowicz P; Gombay E; Heo G
    Stat Med; 2010 Oct; 29(24):2469-79. PubMed ID: 20690108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.